# Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

> **NCT00603954** · PHASE2 · COMPLETED · sponsor: **University of Liege** · enrollment: 107 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Conditioning regimen: TBI + Fludarabine
- **DRUG:** Conditioning regimen:TLI (8 Gy) + ATG

## Key facts

- **NCT ID:** NCT00603954
- **Lead sponsor:** University of Liege
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603954, "Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00603954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*